Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Study sponsor: Altimmune, Inc. · ALT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12Estimated
Enrollment · participants1800Estimated
Source updated2026-11-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.